Nanotechnology Now - Press Release: "Arrowhead Research Corporation President & CEO to Attend Roth Capital Partners Conference"

Home > Press > Arrowhead Research Corporation President & CEO to Attend Roth Capital Partners Conference

Abstract:
Arrowhead (NASDAQ: ARWR) ("Arrowhead") President and Chief Executive Officer Dr. Christopher Anzalone will be in attendance at the 21st Annual Roth Capital Partners OC Growth Stock Conference in Dana Point, California on Tuesday, February 17, 2009 and will be available to meet with members of the investment community. Arrowhead is a nanotechnology company that is commercializing new technologies in the areas of life sciences, electronics, and energy. As owners of key nanotechnology assets in these markets, Arrowhead and its subsidiaries are well-positioned to capitalize on a significant market opportunity. Key partners and customers include Samsung Electronics, Tokyo Electron, Entegris, Inc. and The Battelle Memorial Institute.

Arrowhead Research Corporation President & CEO to Attend Roth Capital Partners Conference

PASADENA, CA | Posted on February 12th, 2009

To arrange a meeting with Dr. Anzalone at the Growth Stock Conference, please contact: Virginia Dadey; Vice President, Investor Relations Telephone: 212.541.3707 Email:

Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The Company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Arrowhead currently has two wholly owned subsidiaries (the "Subsidiaries"), two majority-owned subsidiaries and has minority investments in two development stage nanotechnology companies. The Company's Subsidiaries seek to commercialize a variety of nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and fullerene antioxidants. The Company's minority investments are focused on developing advanced nanomaterials for spinal cord injury and wound healing and drug delivery technology.

Arrowhead's most recent financial results can be found here: www.arrowres.com/publications/090209040951.html. An archived webcast of its financial announcement conference call can be accessed here: phx.corporate-ir.net/playerlink.zhtml?c=120497&s=wm&e=2084013. Visit Arrowhead's home page for additional information: www.arrowheadresearch.com. Arrowhead at a Glance: Recent Price (2/11/09): $0.73 Shares outstanding: 42.9M Market capitalization: $31.3M Fiscal Year End: September 30

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

For more information, please click here

Contacts:

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: